Sanofi Genzyme Charitable Access Program

The Sanofi Genzyme Charitable Access Program (CAP) has been established in the United States through the Sanofi Genzyme Charitable Foundation, Inc. The program is committed to providing Cerezyme® to individuals who:

  • Medically need Cerezyme and
  • Are uninsured or have inadequate insurance coverage for Cerezyme

Qualified individuals with Gaucher disease whose physicians have recommended treatment with Cerezyme may be eligible for the Charitable Access Program. If you are ineligible for our program, your Sanofi Genzyme Case Manager will work with you and your health care providers to explore alternative coverage options.

To be considered for the program, you will be asked to provide the following:

  • A Letter of Intent to Treat with Cerezyme. The letter must be on MD letterhead and your physician must request charitable Cerezyme in the letter and reason why he/she is requesting charitable medication
  • A Statement of Medical Necessity from your physician
  • A completed program application

Your Sanofi Genzyme Case Manager will coordinate with you and your patient to obtain the necessary documentation, including a signed waiver, and keep you updated on the status of your patients application.

Applications are reviewed on a monthly basis and are kept confidential by the Charitable Access Program Committee.

Please note that the Charitable Access Program is considered a temporary program. Patients and their families are expected to continue exploring alternative resources with the assistance of a Sanofi Genzyme Case Manager. These may include:

  • Private insurance
  • Government programs

To learn more about the Sanofi Genzyme's Charitable Access Program or to request an application form call 1-800-745-4447, option 3.

Disclaimer: the Sanofi Genzyme Charitable Access Program may be discontinued at anytime at the discretion of the Charitable Access Program Committee

Indication & Usage

Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:

  1. anemia (low red blood cell count)
  2. thrombocytopenia (low blood platelet count)
  3. bone disease
  4. hepatomegaly or splenomegaly (enlarged liver or spleen)

Important Safety Information

Approximately 15% of patients have developed immune responses (antibodies) to Cerezyme during the first year of therapy. These patients have a higher risk of an allergic reaction (hypersensitivity). Your doctor may periodically test for the presence of antibodies. Serious allergic reactions (anaphylaxis) have been reported in less than 1% of patients. Symptoms suggestive of allergic reaction happened in approximately 7% of patients, and include itching, flushing, hives, swelling, chest discomfort, shortness of breath, coughing, cyanosis (a bluish discoloration of the skin due to diminished oxygen), and low blood pressure. If you have had an allergic reaction to Cerezyme, you and your doctor should use caution if you continue to receive treatment with Cerezyme.

High blood pressure in the arteries of the lungs (pulmonary hypertension) and pneumonia have been observed in less than 1% of patients during treatment with Cerezyme. These are also known complications of Gaucher disease regardless of treatment. If you experience symptoms such as shortness of breath or chest pain, with or without fever, contact your doctor.

Approximately 14% of patients have experienced side effects related to treatment with Cerezyme. Some of these reactions occur at the site of injection such as discomfort, itching, burning, swelling or uninfected abscess. Other side effects, each of which was reported by less than 2% of patients, include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and rapid heart rate. Temporary swelling in the legs has also been observed with drugs like Cerezyme.

Please see Full Prescribing Information (PDF).

You may report side effects to the FDA at 1-800-FDA-1088.

Reference 1. Data on file. Genzyme Corporation; Cambridge, MA.